AstraZeneca confirms FDA grants Fasenra orphan drug designation

AstraZeneca announced that the U.S. Food and Drug Administration has granted orphan drug designation for Fasenra for the treatment of Eosinophilic Granulomatosis with Polyangiitis. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said: “EGPA is a rare, but debilitating inflammatory disease and patients with the disease typically have very high levels of eosinophils. Our clinical trials for Fasenra in severe, eosinophilic asthma show it depletes eosinophils and we are exploring the potential of this medicine to address unmet medical needs in other eosinophil-driven diseases.”
https://thefly.com/landingPageNews.php?id=2827579